Abstract 203P
Background
The immunosuppressive tumor microenvironment (TME) appears to be the main challenge against cancer patients receiving benefits from PD-1/PD-L1-targeting immune checkpoint inhibitors (ICIs), and IL-33/ST2 signaling pathway fulfills critical roles in the TME. However, it remains uncertain whether IL-33 limits the therapeutic efficacy of anti-PD-L1 treatment.
Methods
Cellular and molecular mechanisms of the IL-33/ST2 on anti-PD-L1 treatment in lung cancer were assessed using RNA-seq, scRNA-seq, IB, and IF. A sST2-Fc fusion protein was constructed to target IL-33 and combined with an anti-PD-L1 antibody atezolizumab in lung tumor models. Based on this, bifunctional fusion proteins were generated to block IL-33 in tumors specifically targeting PD-L1. The underlying mechanisms of dual targeting of IL-33 and PD-L1 were revealed using RNA-seq, scRNA-seq, FACS, and IF.
Results
After anti-PD-L1 administration, tumor-infiltrating ST2+ regulatory T cells (Tregs) were elevated. Blocking IL-33/ST2 signaling with sST2-Fc fusion protein potentiated the antitumor efficacy of the PD-L1 antibody by boosting CD8+ T cell responses. Bifunctional fusion protein anti-PD-L1-sST2 demonstrated superior antitumor efficacy compared to combination therapy, not only inhibited tumor progression and extended survival, but also provided long-term protective antitumor immunity. Mechanistically, the superior antitumor activity of targeting both IL-33 and PD-L1 was due to a reduction in immunosuppressive factors, such as Tregs and exhausted CD8+ T cells, while increasing tumor-infiltrating cytotoxic T lymphocytes.
Conclusions
This study demonstrated that IL-33/ST2 is involved in the immunosuppression mechanism of PD-L1 antibody therapy. Blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce a potent antitumor effect. These findings highlight the potential therapeutic strategies for tumor treatment by simultaneously targeting IL-33 and PD-L1.
Legal entity responsible for the study
Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract